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Scandium (Sc) is an element with many industrial applications, but relatively little is known about its physiological and/or
toxicological effects, and very little data are available concerning the role of Sc in chronic renal failure (CRF). This paper examines
the changes in plasma levels of Sc in predialysis patients with CRF and the relationship with blood parameters. The participants
in this trial were 48 patients with CRF in predialysis and 53 healthy controls. Erythrocyte, haemoglobin, and haematocrit counts
in blood were determined, and levels of creatinine, urea, uric acid, albumin, total protein and Sc were measured in plasma. The
glomerular filtration rate (GFR)was calculated using theCockcroft-Gault index.TheCRFpatientswere found to have higher plasma
levels of creatinine, urea, uric acid, albumin, total protein, and Sc and a lower GFR than that the controls. Scandium in plasma was
positively correlated with creatinine and plasma urea and negatively correlated with GFR, haemoglobin, and haematocrit and was
associated with the risk of lower levels of erythrocytes, haemoglobin, and haematocrit. CRF was associated with increases in the
circulating levels of scandium.
1. Introduction
Scandium (Sc) is a rare earth element (REE) that has attracted
research attention because of its potential impact on environ-
mental pollution and its broad range of industrial uses, but
information about its physiological and/or toxicological role
is very limited. Although Sc is considered to present low tox-
icity, under the US Toxic Substances Control Act, scandium
chloride is classed as a poison by the intraperitoneal route and
asmoderately toxic by ingestion [1].Thebioavailability of Sc is
low. In plasma, it is transported primarily by transferrin [2],
but it can also bind to other proteins such as albumin and
globulins [3]. Scandium is widely utilised as a replacement
for toxic heavymetals in technological applications.However,
toxic effects have been reported concerning its propensity
to displace other essential metals such as Ca2+ in many
biochemical events, as a result of its high affinity for proteins.
In this respect, various effects have been described in enzyme
systems and in cell metabolism [4, 5]. Some studies have
examined the likely effects of Sc and of other REEs on the
immune system [6], alterations to gene expression [7], and
mutagenic or teratogenic effects [8]. The toxic effects of
Sc on the liver, kidney, lung, eyes, and skin, as well as its
carcinogenic potential, have also been described [9–11].
In a previous study it was observed that Sc levels in the
nails are associated with a lower risk of acute myocardial
infarction [12]. However, little is known about this ultratrace
element with respect to uraemia. A postmortem study of
uraemic heart failure found a higher concentration of Sc
in the heart than that in the controls [13]. Another study,
seeking to determine Sc nephrotoxicity, showed that the
intraperitoneal injection of scandium chloride provoked a
significant decrease in the glomerular filtration rate (GFR)
and a significant increase in 𝛽-2microglobulin and𝑁-acetyl-
beta-𝐷-glucosaminidase, suggesting that it may provoke
alterations to the renal tubular function [14].
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Given the limited information available on the role of
Sc in chronic renal failure (CRF) and its impact on renal
function and other physiological processes, the aim of this
study is to investigate changes in the plasma levels of Sc
in predialysis patients with CRF and their relation to the
biochemical and haematological parameters commonly used
in monitoring such patients.
2. Materials and Methods
2.1. Patients. The participants in this cross-sectional trial
were patients with CRF in predialysis that attended at the
nephrology outpatient clinic of the Virgen de las Nieves
University Hospital (Spain). The following inclusion criteria
were applied: serum creatinine concentration >25mg/dL,
plasma creatinine clearance between 10 and 45mL/min,
stable clinical condition (stable blood pressure, no special
diet, and no digestive system or systemic disease, neoplasias,
or treatment with corticosteroids or immunosuppressors),
corrected metabolic acidosis and lipid alterations, and age
between 18 and 70 years. Control sample was obtained at
random within adults aged 18–70 years old living in Granada
(Spain). Control participants were asked whether they had
any acute or chronic illness andwere included if they were (or
appeared to be) in good health; pregnant and lactating were
excluded. The sample of patients consisted of 48 individuals
(22 women, 26 men) aged 18 to 70 years with a mean age
of 52.7 ± 16.4 years (𝑋 ± SD). The controls were 53 healthy
persons (24 men and 29 women), with a mean age of 44.6 ±
13.1 years. All participants provided their consent by signing
an Informed Consent Form.The study was authorised by the
Hospital’s Ethics Committee.
Body weight was measured with a portable digital scale
(Tefal, Sensitive Computer 9202 series 2/0, France) with a
precision of 0.1 kg, and height was measured with a portable
stadiometer (Holtain Portable, London, UK) with a preci-
sion of 0.1 cm. All measurements were obtained following
the techniques and recommendations of the International
Biological Programme by personnel suitably trained for this
task.
2.2. Analytical Methods. In the morning, blood was collected
(10mL) in fasting conditions, in tubes that contained lithium
heparin as an anticoagulant (Venoject, Terumo Corporation,
Leuven, Belgium).The samples were centrifuged at 3000 rpm
for 15min at 20∘C to separate the plasma and were stored at
−80∘C until analysis.
Red blood cells (RBC) and haemoglobin (Hb) were
determined with a Sysmex KX-21 automated haematology
analyser (Sysmex Corporation, Japan). Haematocrit (Hct)
was determined by centrifugation at 12000 g for 5min at 20∘C.
Mean cell volume (MCV), mean cell haemoglobin
(MCH), and mean corpuscular haemoglobin concentration
(MCHC) were calculated from the RBC, Hb, and Hct.
Creatinine in plasma and urine, and urea, uric acid,
albumin, and total protein concentrations in plasma were
measured with enzymatic colorimetric tests in a Hitachi
Modular 𝑃 autoanalyser (Roche Diagnostics, Grenzach, Ger-
many). Glomerular filtration rate (GFR) was estimated in
patients by creatinine clearance, by the determination of
diuresis and serum and urinary creatinine at 24 hours. GFR
was also measured in the patients and the controls using the
Cockcroft-Gault index = (140 − age/72 × creatinine) ×weight
(×0.85 for women) [15].
Determination of Sc in plasma was performed by induc-
tively coupled plasma mass spectrometry (ICP-MS) (Agilent
4500, Germany). All the materials used in the analysis were
previously cleaned with super-pure nitric acid and ultrapure
water (18.2Ω) obtained using a Milli Q system. Samples were
prepared by attack with nitric acid and hydrogen peroxide
(super-pure quality, Merck), in a microwave digester (Mile-
stone, Sorisole, Italy). When the sample had been digested,
the extract was collected and made up to a final volume of
10mL for subsequent analysis.
Calibration curves were prepared following the Ga addi-
tion technique as an internal standard, using mother solu-
tions of 1000mg/L of each element (Merck).
The total content of Sc in plasma was analysed by ICP-
MS [9], and the accuracy of the method was evaluated by
analysis of suitable certified reference materials, Seronorm
(Billingstad, Norway), and by recovery studies in samples of
organs enriched with Sc standards. The value obtained for
Sc was 22.23 ± 8.6mg/L (certified value, 9.4–26.2 ng/L). The
mean of five separate determinations was used.
2.3. Statistical Analysis. All variables and indexes were anal-
ysed with descriptive statistics, and the results are reported
as the mean and standard deviation. When the data were
distributed normally according to the Kolmogorov-Smirnov
test, we used parametric tests, that is, Student’s 𝑡 test for
independent or related samples. For variables that required
nonparametric testing, the Mann-Whitney test for unrelated
samples was used. Linear regression analysis was used to
obtain bivariate correlations; Pearson’s correlation coefficient
was calculated for 95% confidence levels. Multiple logistic
regression analysis was used to estimate the degree of associ-
ation between Sc plasma values (dependent variable) and the
anthropometric, biochemical, and haematological variables
studied. The model was adjusted for age and sex for each of
the study variables. All analyses were carried out with version
15.0 of the Statistical Package for Social Sciences (SPSS Inc.,
Chicago, IL). Differences were considered significant at the
5% probability level.
3. Results
Table 1 shows the mean values and standard deviations
for patients and controls, by age, anthropometric variables
(weight, height, BMI), plasma parameters indicative of renal
function (serum creatinine, creatinine clearance, Cockcroft-
Gault index, urea/creatinine ratio, uric acid in plasma, and
total proteins in plasma), blood count (RBC, haemoglobin,
Hct, MCV, MCH, and MCHC), and serum levels of Sc. The
table also shows the data stratified into percentiles (𝑃25, 𝑃50,
and 𝑃75). There was found to be a significant worsening of
all plasma parameters indicative of renal function, and of the
blood count, except for the MCV, MCH, andMCHC indices,
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Table 1: Anthropometric, biochemical, and haematological variables and plasma levels of Sc in patients and controls.
Patients𝑁 = 48 Controls𝑁 = 53
Mean ± SD 𝑃25 𝑃50 𝑃75 Mean ± SD 𝑃25 𝑃50 𝑃75
Age (years) 52.7 ± 16.4 41 59 65 44.6 ± 13.1 30 48 56
Height (m) 1.63 ± 0.10 1.56 1.64 1.70 1.63 ± 0.09 1.57 1.61 1.69
Weight (kg) 73.1 ± 14.0 62.0 73.0 77.8 74.9 ± 12.9 65.0 75.3 86.0
BMI (kg/m2) 27.6 ± 5.4 23.8 26.8 30.4 28.3 ± 4.3 25.3 27.5 31.9
Plasma creatinine (mg/dL) 3.37 ± 1.28 2.57 3.32 3.98 0.77 ± 0.12a 0.70 0.80 0.85
Glomerular filtration rate (mL/min/1.73m2) 23.8 ± 8.9 17.3 22.00 28.93 — — — —
Cockcroft-Gault index 29.4 ± 19.6 17.9 25.68 32.06 114 ± 21a 101 110 122
Plasma urea (mg/dL) 104 ± 40 76 100 130 31.5 ± 6.1a 27.0 31.0 37.0
Urea/creatinine ratio 32.5 ± 9.1 27.8 32.0 38.2 41.8 ± 9.8a 35.5 40.0 47.7
Plasma uric acid (mg/dL) 7.1 ± 1.2 6.3 7.4 10.1 5.5 ± 1.4a 3.7 4.8 6.4
Plasma total protein (g/dL) 7.1 ± 0.6 6.6 7.0 7.5 6.7 ± 0.5a 6.35 6.73 6.96
RBC (×106/𝜇L) 4.2 ± 0.5 3.8 4.2 4.7 4.8 ± 0.4a 4.5 4.7 5.0
Hb (g/dL) 12.4 ± 1.8 11.0 12.2 13.8 14.5 ± 1.6a 13.7 14.4 15.1
Hct (%) 38.1 ± 5.5 34.4 37.4 41.5 44.7 ± 5.0a 42.0 44.2 46.8
VCM (fL) 91 ± 5 88.8 91.9 94.7 93.4 ± 7.6 89.2 93.3 97.2
HCM (pg) 29.6 ± 2.4 29.0 30.0 31.0 30.4 ± 2.8 29.0 30.2 31.4
MCHC (g/dL) 32.7 ± 0.9 32.0 33.0 33.0 32.5 ± 1.8 31.4 32.4 33.3
Plasma Sc (ng/L) 54.4 ± 19.1 45.7 58.9 67.9 28.6 ± 11.9a 18.9 28.6 35.7
𝑃 indicates percentile.
Patients versus controls a𝑃 < 0.05.
in the patients with respect to the controls. There was also a
significant increase in circulating levels of Sc in the patients
with CRF.
Table 2 shows the differences between the different vari-
ables studied, by gender and age. A comparison of the patients
and the controls, with respect to gender, showed that the
results were very similar for men and women, with the same
differences as those obtained for the total population.
For the age-related study,we examined two age groups (50
years or less, and over 50 years). This cutoff point was chosen
because this is the age at which certain physiological effects
of aging, such as the menopause in women and changes
in body composition in both genders, begin to appear [16].
The older patients presented higher mean values of BMI,
plasma creatinine, andMCHand lower levels ofGFR than the
younger patients. The controls aged over 50 years presented
lower values for body weight and Cockcroft-Gault index but
higher levels of plasma urea and a higher urea/creatinine
ratio than in the controls aged under 50 years. Significant
differences were found for all of the parameters indicative
of renal and haematological function between the younger
group of patients and their controls, and the situation was
very similar for the comparison between the older patients
and the respective controls, although in the latter case there
were no differences with respect to total plasma proteins and
the haematological indices (Table 2).
Table 3 shows the results obtained for the patients and
controls adjusted for BMI. Both populations were divided
into three groups: normal weight (BMI ≤ 25), overweight
(BMI 25.00–29.99), and obese (BMI > 30).When the patients
and controls were studied independently, no significant
changes were observed between the parameters of renal and
haematological function due to BMI. Thus, the comparative
study of patients and controls for each of the BMI groups
revealed very similar changes. In all three groups (BMI ≤ 25,
25.00–29.99 BMI and BMI > 30) significant differences were
observed in most renal function parameters, and among the
haematological parameters there were differences for RBC,
Hb, andHct.The Sc content in plasmawas higher in the three
groups of patients than in the respective controls.
Table 4 reveals significant Pearson correlation coefficients
between the plasma content of Sc and the anthropometric,
renal function, and haematological variables studied.
Table 5 shows the significant associations (odds ratio and
95%CI) for plasma Sc with the different variables studied.
4. Discussion
Given the scant information available on the potential toxicity
of Sc, on its possible role in chronic renal failure (CRF) and
on its influence on renal function and other physiological
parameters, the aim of this paper is to study the changes
in plasma levels of Sc in predialysis patients with CRF
and its relationship with biochemical and haematological
parameters of clinical interest in monitoring such patients.
Significant differences between the patients and controls
were found with respect to all plasma parameters indicative
of renal function, and typical of uraemia, which is consistent
with expectations for individuals diagnosed with CRF. Thus,
there were higher values for serum creatinine, the Cockcroft-
Gault index reflected a low GFR, and there were high
concentrations of urea, uric acid, and total protein in plasma
(Table 1).
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Table 2: Anthropometric, biochemical, and haemogram variables and plasma levels of Sc, by gender and age group.
Gender Age groups

















Age (years) 48.1 ± 18.5 58.1 ± 11.8b 43.7 ± 13.8 45.3 ± 12.8a 37.3 ± 12.9 64.6 ± 4.6c 30.3 ± 5.3d 54.6 ± 4.6c, d
Height (m) 1.66 ± 0.08 1.60 ± 0.11 1.66 ± 0.09 1.60 ± 0.08b 1.65 ± 0.09 1.62 ± 0.10 1.63 ± 0.10 1.62±0.08
Weight (kg) 75.2 ± 15.0 70.4 ± 12.5 74.7 ± 12.4 75.0 ± 13.6 69.5 ± 16.9 74.8 ± 12.2 76.1 ± 14.3 73.3 ± 11.1c
BMI (kg/m2) 27.5 ± 5.2 27.7 ± 5.7 27.0 ± 3.1 29.4 ± 5.0b 25.2 ± 3.9 28.7 ± 5.7c 28.7 ± 4.8d 27.9 ± 3.9d
Plasma creatinine
(mg/dL) 3.80 ± 1.20 2.87 ± 1.22
b 0.79 ± 0.14a 0.76 ± 0.12 3.20 ± 1.29 3.46 ± 1.29 0.79 ± 0.13d 0.75 ± 0.11d
Glomerular filtration
rate (mL/min/1.73m2) 25.3 ± 9.5 21.6 ± 7.8 — — 28.4 ± 9.2 21.8 ± 8.2
c — —
Cockcroft-Gault index 26.9 ± 9.6 32.3 ± 27.0b 118 ± 22a 110 ± 18a 35.8 ± 18.1 26.1 ± 19.7 118 ± 24d 108 ± 14c, d
Plasma urea (mg/dL) 107 ± 38 101 ± 42 29.8 ± 5.3a 33.0 ± 6.3a 101 ± 51 106 ± 33 29.5 ± 4.8d 34.0 ± 6.6c, d
Urea/creatinine ratio 29.5 ± 9.4 35.9 ± 7.4b 38.9 ± 9.1a 44.2 ± 10.0a 32.2 ± 9.3 32.6 ± 9.1 38.1 ± 7.2d 46.4 ± 10.8c, d
Plasma uric acid
(mg/dL) 7.5 ± 1.2 6.8 ± 1.8 5.6 ± 1.7
a 5.5 ± 1.1a 7.2 ± 1.1 7.1 ± 1.3 5.9 ± 1.6d 5.1 ± 1.0d
Plasma total protein
(g/dL) 7.0 ± 0.6 7.1 ± 0.6 6.7 ± 0.3 6.8 ± 0.6 7.1 ± 0.7 7.0 ± 0.6 6.7 ± 0.5
d 6.9 ± 0.5
RBC (×106/𝜇L) 4.2 ± 0.4 4.2 ± 0.7 4.9 ± 0.3a 4.7 ± 0.5a 4.2 ± 0.5 4.2 ± 0.6 4.8 ± 0.4d 4.7 ± 0.4d
Hb (g/dL) 12.5 ± 1.8 12.4 ± 1.9 14.5 ± 1.2a 14.4 ± 1.8a 12.2 ± 1.6 12.5 ± 1.9 14.3 ± 0.9d 14.7 ± 2.1d
Hct (%) 38.1 ± 4.9 38.1 ± 6.3 44.5 ± 4.1a 44.8 ± 5.7a 37.3 ± 4.7 38.4 ± 5.8 43.7 ± 3.2d 45.9 ± 6.5d
VCM (fL) 90.1 ± 5.6 92.1 ± 5.1 93.5 ± 7.6 93.3 ± 7.8 89.0 ± 6.6 91.8 ± 4.6 93.6 ± 7.0d 93.2 ± 8.5
HCM (pg) 29.1 ± 2.7 30.4 ± 1.7 30.6 ± 2.6 30.2 ± 3.0 28.5 ± 3.1 30.1 ± 1.9c 30.7 ± 2.3d 29.9 ± 3.3
MCHC (g/dL) 32.6 ± 1.1 32.7 ± 0.5 32.8 ± 1.8 32.3 ± 2.0 32.7 ± 0.8 32.6 ± 0.9 32.9 ± 2.0 32.1 ± 1.6
Plasma Sc (ng/L) 60.8 ± 16.5 51.9 ± 20.8 26.0 ± 10.6a 30.5 ± 12.7a 55.1 ± 20.0 59.6 ± 19.1 29.4 ± 11.5d 27.5 ± 12.9d
Values are mean ± SD; gender:a patients versus controls, bmen versus women; age group; c ≤50 years versus >50 years, dpatients versus controls. 𝑃 < 0.05.
In the uraemic patients, the haemogram study revealed
lower levels of red blood cells, haemoglobin, and haematocrit,
compared with the healthy controls. This outcome is due to
the loss of renal mass in patients with CRF, associated with
endocrine disorders such as a deficiency of erythropoietin
(95% of which is produced in the kidney, and which is neces-
sary for RBCmaturation), which leads to the development of
anaemia [17]. It may also be caused by the retention of toxic
metabolites that inhibit haematopoiesis and shorten average
erythrocyte life [18, 19].
The finding of increased circulating levels of Sc (up to
100% higher) in the patients in the present study is consistent
with previous studies, which have reported raised levels of
Sc in the heart of uraemic patients who died from heart
failure [13]. This increase in Sc levels could be related to
the worsening of the parameters relating to the CRF; in this
respect, Tanida et al. [14] reported that the intraperitoneal
injection of Sc to rats produces a decrease in the GRF. These
authors suggest that the Sc colloidal conjugates that are
deposited in glomeruli might be the cause of the lower GRF.
They also found that the Sc provoked a significant increase
in 𝛽-2 microglobulin and𝑁-acetyl-beta-𝐷-glucosaminidase,
suggesting impaired renal tubular function. These results
lead us to believe that the damage caused by CRF would
reduce the GFR of Sc, thus producing the formation of the
tissue deposits observed in the heart [13], exacerbating the
alterations in renal function, and facilitating the progress of
the disease. The linear correlations observed in the present
study between plasma levels of Sc and the biochemical
parameters of renal function (Table 4) support the above
comments. Furthermore, we found high levels of plasma
Sc, associated with the risk of low haematological values
(Table 5), which also supports the view that the accumulation
of Sc favours kidney damage, facilitating the onset of anaemia
in patients with CRF. However, it is also possible that the Sc
may exercise a toxic effect in the bone marrow and/or the
erythrocytes.
The results obtained do not reflect, in the patient group
or in the control group, any significant differences between
the studied variables as a result of gender, age, or BMI. The
only relevant findings in this respect were in the comparisons
between the patient subgroups (male, female, age ≤50 years,
age >50 years, normal weight, overweight, and obese) com-
pared to their respective controls (Tables 2 and 3) and these
differences were very similar to those found in comparisons
of the total populations of both groups (Table 1). Our results
show that in neither the patients nor the controls were plasma
levels of Sc affected by gender or by BMI (Tables 2 and 3).
However, there was a significant association between high
levels of plasma Sc and age (Table 5), perhaps because with
The Scientific World Journal 5














Age (years) 47.4 ± 18.1 51.5 ± 17.1 61.9 ± 7.2 48.7 ± 11.7 42.6 ± 13.0 45.9 ± 14.1
Height (m) 1.68 ± 0.08 1.61 ± 0.08 1.58 ± 0.11 1.65 ± 0.04 1.62 ± 0.10 1.62 ± 0.09
Weight (kg) 64.5 ± 7.4 71.8 ± 7.6 87.0 ± 16.8b, c 61.4 ± 6.8 71.8 ± 9.4a 88.8 ± 8.6b, c
BMI (kg/m2) 22.8 ± 1.5 27.5 ± 1.3a 34.5 ± 4.5b, c 22.5 ± 2.1 27.3 ± 1.8a 33.8 ± 2.3b, c
Plasma creatinine (mg/dL) 3.42 ± 1.22 3.36 ± 1.29 3.32 ± 1.46 0.71 ± 0.15d 0.77 ± 0.12d 0.82 ± 0.10d
Glomerular filtration rate
(mL/min/1.73m2) 24.9 ± 9.7 22.0 ± 7.3 24.1 ± 10.1 — — —
Cockcroft-Gault index 25.0 ± 10.1 29.4 ± 19.4 35.7 ± 28.1 108 ± 11d 112 ± 19d 121 ± 25d
Plasma urea (mg/dL) 103 ± 37 114 ± 48 95 ± 33 30.8 ± 7.1d 31.6 ± 6.2d 32.1 ± 5.6d
Urea/creatinine ratio 30.7 ± 6.8 35.7 ± 11.5 30.9 ± 8.1 44.6 ± 12.3d 41.9 ± 9.4 39.9 ± 9.4d
Plasma uric acid (mg/dL) 7.2 ± 1.4 7.3 ± 1.0 7.0 ± 1.1 4.7 ± 1.1d 6.0 ± 1.1d 5.1 ± 1.0d
Plasma total protein (g/dL) 7.1 ± 0.7 6.9 ± 0.6 7.1 ± 0.4 7.1 ± 0.8 6.7 ± 0.4 6.5 ± 0.3d
RBC (×106/𝜇L) 4.1 ± 0.6 4.3 ± 0.4 4.1 ± 0.6 4.6 ± 0.3d 4.7 ± 0.4d 4.9 ± 0.6d
Hb (g/dL) 12.2 ± 1.8 12.9 ± 2.1 12.2 ± 1.6 15.4 ± 2.6d 14.2 ± 1.2d 14.4 ± 1.2d
Hct (%) 37.3 ± 5.5 39.5 ± 5.7 37.2 ± 5.2 46.7 ± 8.5d 44.1 ± 4.1d 44.5 ± 3.8d
VCM (fL) 90.6 ± 5.3 91.1 ± 5.2 91.2 ± 6.2 95.9 ± 7.2 93.0 ± 8.0 92.6 ± 7.3
HCM (pg) 29.9 ± 2.1 29.1 ± 3.0 29.9 ± 1.9 31.8 ± 3.3 30.1 ± 2.8 29.9 ± 2.4
MCHC (g/dL) 32.7 ± 0.6 32.6 ± 1.1 32.7 ± 1.0 33.1 ± 2.3 32.4 ± 1.9 32.3 ± 1.4
Plasma Sc (ng/L) 54.5 ± 19.7 66.3 ± 17.0 50.7 ± 18.4 28.8 ± 14.4d 23.5 ± 7.6d 36.1 ± 12.7d
Values are mean ± SD; aIMC ≤ 25 versus 25 > IMC ≤ 30; b25 ≤ versus IMC < 30; c25 > IMC ≤ 30 versus IMC < 30; dpatients versus controls. 𝑃 < 0.05.
Table 4: Significant correlation coefficients between the study
variables and plasma levels of scandium.
Plasma Sc (ng/L)
Plasma creatinine (mg/dL) 0.675a
Cockcroft-Gault index −0.664a






increasing age the disease tends to worsen and thereby Sc
accumulates, which may further aggravate the disease.
5. Conclusions
The results presented show that chronic kidney disease is
associated with increases in circulating levels of scandium
and that these increases may aggravate the disease. However,
further studies are needed to better determine the possible
toxicological effects of scandium on the kidney. We hope
the information presented in this paper may be useful in
designing future studies.
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Table 5: Significant odds ratio and 95% confidence intervals, for






>50 years 4.38 (1.50–12.90)a
RBC
>4 (women) >4.5 (men) (×106/𝜇L) 1.00
<4 (women) <4.5 (men) (×106/𝜇L) 4.76 (1.19–19.04)a
Haemoglobin
>12 (women) >13 (men) (mg/dL) 1.00
<12 (women) <13 (men) (mg/dL) 13.13 (2.33–74.02)a
Haematocrit
>36 (women) >40 (men) (%) 1.00
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